The short answer: Pembrolizumab (Keytruda) is an immunotherapy medicine given as a drip; it is not chemotherapy. For cervical cancer (bachedani ke muh ka cancer, बच्चेदानी के मुँह का कैंसर) it is used in two main situations: added to chemoradiation for some high-risk cancers that have spread locally, and added to chemotherapy for some cancers that have come back or spread. In large trials it helped selected women live longer. It is not right for every cervical cancer, it is expensive, and approvals can differ in India, so the team confirms whether it is approved, suitable and affordable for you.
Pembrolizumab (brand name Keytruda) is an immunotherapy used for some women with cervical cancer. It may be added to chemoradiation for certain newly diagnosed, high-risk locally advanced cancers, or combined with other medicines for some persistent, recurrent or metastatic cancers. It is not suitable for every cervical cancer, and the tests and evidence used to make the decision depend on the treatment setting. For how immunotherapy works across women’s cancers and who may qualify, see immunotherapy and eligibility.
On This Page
What Is Pembrolizumab (Keytruda), and How Does It Work?
Pembrolizumab and Keytruda are two names for the same medicine. It is a type of immunotherapy called a PD-1 immune checkpoint inhibitor. Cancer can use checkpoint signals to reduce an immune attack. Pembrolizumab blocks one of these signals and can help immune cells recognise and attack cancer.
It is different from chemotherapy. Chemotherapy directly damages rapidly dividing cells, while pembrolizumab changes how the immune system responds. The treatments may be used together because they work in different ways. Pembrolizumab is given through a drip into a vein; it is not a tablet and it is not a vaccine. It is one part of cervical cancer diagnosis and care and is used alongside, not instead of, radiotherapy, chemotherapy or surgery.
When Is Pembrolizumab Used for Cervical Cancer?
The phrase “immunotherapy for cervical cancer” can refer to very different situations. A decision should begin with the stage, whether this is a first diagnosis or a recurrence, the aim of treatment, previous treatment, pathology and relevant biomarkers.
| Clinical situation | How pembrolizumab may fit | What the decision depends on |
|---|---|---|
| Newly diagnosed, high-risk locally advanced cervical cancer | It may be given with cisplatin-based external-beam radiotherapy and brachytherapy, then continued after chemoradiation for an appropriate patient. | Stage and risk group, fitness for definitive chemoradiation, immune-related risks, local approval and access. Brachytherapy remains part of definitive treatment when indicated. |
| Persistent, recurrent or metastatic cervical cancer | It may be combined with platinum chemotherapy and paclitaxel, sometimes with bevacizumab, for selected patients. In another setting it may be used alone after previous chemotherapy. | PD-L1 and other eligible biomarkers where applicable, previous medicines, sites of disease, symptoms, general health, bleeding or fistula risk, and whether curative local treatment remains possible. |
The exact approved use and availability can differ between countries and can change over time. A treatment used for Stage III–IVA disease alongside chemoradiation should not be copied automatically into an earlier-stage, postoperative or recurrent-cancer plan.
Do I Need a PD-L1 Test Before Pembrolizumab?
Sometimes, but not in every treatment setting. PD-L1 is a protein measured in tumour tissue. For some persistent, recurrent or metastatic cervical-cancer uses, the report may give a combined positive score (CPS), and eligibility can depend on that result. For pembrolizumab given with chemoradiation in the studied high-risk locally advanced setting, treatment selection is based principally on the clinical setting rather than using PD-L1 in the same way.
Ask the treating team to confirm:
- the exact stage and whether the cancer is newly diagnosed, persistent, recurrent or metastatic;
- the pathology type and whether enough tumour tissue is available;
- whether PD-L1 CPS, microsatellite instability (MSI), mismatch-repair deficiency (dMMR) or tumour mutational burden is relevant to this particular proposed use;
- whether the laboratory test is validated and how its result changes the plan; and
- whether previous immunotherapy affects the available options.
A positive biomarker does not guarantee that treatment will work. A negative PD-L1 result also should not be interpreted without knowing the exact clinical indication being considered.
How Is Pembrolizumab Treatment Given?
Pembrolizumab is given by intravenous infusion on a repeating schedule. The dose interval, number of cycles and medicines given with it depend on the treatment plan. In high-risk locally advanced disease, the KEYNOTE-A18 regimen gave pembrolizumab every 3 weeks for 5 cycles during chemoradiation, then every 6 weeks for 15 more cycles as maintenance treatment. Chemoradiation still included external-beam radiotherapy, cisplatin and brachytherapy.
Before and during treatment, the team usually reviews symptoms and checks blood counts, liver and kidney function, and thyroid function. Other tests may be needed if symptoms suggest inflammation in a particular organ. Scans assess the cancer at planned intervals, but the timing should reflect the disease and treatment setting.
Do not start steroids, stop immunotherapy or delay an infusion without contacting the treating oncology team. Steroids can be essential for an immune-related reaction, but the dose and timing require medical supervision.
What Benefit Can Pembrolizumab Offer?
For eligible patients, clinical trials have shown that adding pembrolizumab to established treatment can delay progression and, in specific settings, improve survival. These are results across groups of trial participants; they cannot predict exactly how long an individual person will respond.
In the KEYNOTE-A18 trial of 1,060 women with newly diagnosed high-risk locally advanced cervical cancer, pembrolizumab was studied with definitive chemoradiation and then continued afterwards. The benefit that supported treatment adoption was clearest in the FIGO 2014 Stage III–IVA group. In plain numbers, about 83 in 100 women who had pembrolizumab added were alive three years later, compared with about 75 in 100 who had chemoradiation alone. The result does not mean that immunotherapy replaces radiation, cisplatin or brachytherapy.
For persistent, recurrent or metastatic disease, KEYNOTE-826 studied pembrolizumab with platinum-based chemotherapy and paclitaxel, with or without bevacizumab. Adding pembrolizumab helped women live longer than chemotherapy alone; the main analyses focused on tumours with a PD-L1 combined positive score (CPS) of 1 or more. The likely benefit and suitable combination depend on the tumour biomarkers and on whether bevacizumab is safe for that patient.
Will Pembrolizumab Make My Quality of Life Worse?
Not necessarily, but “quality of life stayed stable” is an average study finding, not a promise for every patient. In the patient-reported-outcome analysis from KEYNOTE-A18, adding pembrolizumab to chemoradiation did not produce a clinically meaningful worsening in overall health-related quality of life compared with chemoradiation alone during the measured period. Both groups were receiving intensive treatment, and individual experiences varied.
The finding is reassuring because a treatment that improves cancer control should also be assessed for its effect on daily life. It does not mean there are no extra side effects, that every symptom remains stable, or that the experience will be identical after treatment ends. The trial population had newly diagnosed high-risk locally advanced disease; its quality-of-life result should not automatically be applied to every recurrent or metastatic situation.
Quality of life can be affected by fatigue, nausea, bowel or bladder symptoms, menopausal symptoms, sexual health, anxiety, work and travel for treatment. Reporting these concerns early allows the team to treat reversible causes and arrange nutrition, pain, pelvic-health or psychological support where needed.
What Side Effects Require Attention?
Pembrolizumab can cause familiar symptoms such as fatigue, rash, itching, nausea, diarrhoea and changes in thyroid function. When it is combined with chemotherapy and radiation, symptoms may come from more than one treatment.
Because pembrolizumab activates immune responses, it can also cause the immune system to inflame healthy organs. These reactions can occur during treatment or after it has stopped. Contact the oncology team promptly for a new or worsening symptom, especially:
- persistent diarrhoea, blood or mucus in stools, or severe abdominal pain;
- new cough, breathlessness or chest pain;
- yellow skin or eyes, dark urine, severe nausea or pain on the right side of the abdomen;
- marked tiredness, dizziness, fainting, persistent headache, unusual thirst or major weight change;
- reduced urine, swelling or blood in the urine;
- a widespread, blistering or painful rash;
- new weakness, numbness, confusion, vision change or severe muscle pain; or
- fever or any symptom that is rapidly becoming worse.
Many immune-related reactions can be controlled when identified early. Waiting until the next scheduled visit can allow a manageable reaction to become serious.
Who May Need a Different Treatment Plan?
An oncology team needs additional care when considering pembrolizumab for someone with an active autoimmune disease, an organ or stem-cell transplant, previous severe immune-related toxicity, lung inflammation, significant infection, or medicines that suppress the immune system. Pregnancy and breastfeeding require specific advice because of potential harm to a developing baby.
General fitness, kidney and liver function, the ability to complete chemoradiation, previous pelvic radiation, neuropathy, hearing problems and other illnesses can change the overall regimen. For recurrent pelvic disease, bleeding, a fistula, bowel involvement and previous radiation can influence whether bevacizumab or another component is safe.
This does not mean that one of these factors automatically rules out treatment. It means the benefit and risk need individual review, sometimes involving medical oncology, radiation oncology and gynaecological oncology together.
Questions to Ask Before Starting Pembrolizumab
- What is the aim in my case: cure, reducing recurrence risk, controlling cancer or relieving symptoms?
- Which treatment setting and evidence apply to me?
- Do I need PD-L1 or another biomarker test, and what is my actual result?
- Which chemotherapy, radiation or targeted medicine will be given with it?
- How long is treatment planned, and what would make you pause or stop it?
- Which symptoms should I report the same day?
- How will thyroid, liver, kidney and other immune effects be monitored?
- How will response be assessed, and what are the alternatives if it does not work?
- What costs, insurance authorisation and travel should we plan for?
Frequently Asked Questions
Are Keytruda and pembrolizumab the same medicine?
Yes. Keytruda is the brand name; pembrolizumab is the generic medicine name.
Is pembrolizumab chemotherapy?
No. It is an immune checkpoint inhibitor. It may be given alongside chemotherapy, radiation and sometimes bevacizumab, depending on the clinical setting.
Does everyone with Stage 3 cervical cancer need pembrolizumab?
No. The stage and risk group, health, planned chemoradiation, potential immune risks, availability and applicable approval all matter. The treatment must be discussed as part of the complete definitive-treatment plan.
Does pembrolizumab replace brachytherapy?
No. When definitive chemoradiation is the plan, pembrolizumab does not replace internal radiation (brachytherapy). Omitting or delaying brachytherapy can weaken curative treatment.
Does a PD-L1-positive result mean pembrolizumab will definitely work?
No. PD-L1 can help select treatment in certain settings, but it does not guarantee a response. Other clinical factors remain important.
How much does Keytruda cost in India?
Pembrolizumab is an expensive medicine, and the total cost depends on the dose, how many cycles are planned, the chemotherapy or radiotherapy given with it, tests, and the hospital. Ask the hospital for a written estimate before starting, and ask about insurance, government schemes and any patient-assistance programmes. Approvals and availability can differ in India, so the team confirms what applies to your situation.
Can side effects appear after treatment has finished?
Yes. Immune-related effects can occur during treatment and sometimes after the last dose. Tell any clinician who treats you that you have received an immune checkpoint inhibitor.
Can pembrolizumab cure recurrent cervical cancer?
Some people can have a durable response, but recurrent or metastatic disease usually requires a long-term control strategy. The realistic aim depends on where the cancer has returned and whether surgery or radiation can still offer curative local treatment.
Related Cervical Cancer Guidance
Read the complete guide to cervical cancer diagnosis and treatment, the detailed Stage 3 chemoradiation and brachytherapy pathway, and guidance on obtaining a gynaecological cancer second opinion.